Primary high-grade osteosarcoma: Comparison between preadolescent and older patients

Journal of Pediatric Hematology/Oncology

Volumn 27, Issue 3, 2005, Pages 129-134

  Bacci, Gaetano ^a,d   Longhi, Alessandra ^a   Bertoni, Franco ^a   Bacchini, Patrizia ^a   Ruggeri, Pietro ^b   Versari, Michela ^a   Picci, Piero ^c  

^a Istituti Ortopedici Rizzoli ^*  (Italy)

^b Istituti Ortopedici Rizzoli   (Italy)

^c Laboratory of Oncologic Research   (Italy)

^d RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

Author keywords

Chemotherapy; Osteosarcoma; Preadolescence; Prognosis

Indexed keywords

ANTINEOPLASTIC AGENT;

ADJUVANT CHEMOTHERAPY; ADOLESCENCE; ADOLESCENT; ADULT; AMPUTATION; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CHILD; CLINICAL PROTOCOL; COMPARATIVE STUDY; CONTROLLED STUDY; EPIDEMIOLOGICAL DATA; FEMALE; FOLLOW UP; HUMAN; LIMB SALVAGE; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; METASTASIS; OSTEOSARCOMA; PATIENT COMPLIANCE; PATIENT SELECTION; PREOPERATIVE EVALUATION; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SALVAGE THERAPY; SEX RATIO; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TUMOR LOCALIZATION;

ADOLESCENT; ADULT; AGE FACTORS; BONE NEOPLASMS; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; OSTEOSARCOMA; PROGNOSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 15444367666     PISSN: 10774114     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mph.0000155860.38641.83     Document Type: Review

References (26)

1. Winkler K, Beron G, Kotz R, et al. Neoadjuvant chemotherapy for osteogenic sarcoma: results of a cooperative German/Austrian study. J Clin Oncol. 1984;2:617-624.
2. Winkler K, Beron G, Delling G, et al. Neoadjuvant chemotherapy for osteogenic sarcoma: results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response. J Clin Oncol. 1988;6:329-337.
3. Bacci G, Ferrari S, Longhi A, et al. High-dose ifosfamide in combination with high-dose methotrexate, doxorubicin and cisplatin in the neoadjuvant treatment of extremity osteosarcoma: preliminary results of an Italian Sarcoma Group/Scandinavian Sarcoma Group pilot study. J Chemother. 2002;14:198-206.
4. Burgers JM, van Glabbeke M, Busson A, et al. Osteosarcoma of the limb. Report of the EORTC-SIOP 03 trial 20781 investigating the value of adjuvant treatment with chemotherapy and/or prophylactic lung irradiation. Cancer. 1988;61:1024-1031.
5. Geidel S, Garr M, Gravinghoff L, et al. Cardiomyopathy after osteosarcoma treatment: a contribution to the cardiotoxicity of adriamycin. Klin Padiatr. 1991;203:257-261.
6. Fuchs N, Bielack SS, Epler D, et al. Long-term results of the cooperative German-Austrian-Swiss Osteosarcoma Study Group's protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs. Ann Oncol. 1986;9:893-899.
7. Goorin AM, Perez-Atayde A, Gebhardt M, et al. Weekly high-dose methotrexate and doxorubicin for osteosarcoma; the Dana Farber Cancer Institute/the Children's Hospital Study III. J Clin Oncol. 1987;5:1178-1184.
8. Hudson M, Jaffe MR, Jaffe N, et al. Pediatric osteosarcoma: strategies, results and prognostic factors derived from a 10-year experience. J Clin Oncol. 1990;8:1988-1997.
9. Meyers PA, Heller G, Healey J, et al. Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience. J Clin Oncol. 1992;10:5-15.
10. Provisor AJ, Ettinger LJ, Nachman JB, et al. Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children's Cancer Group. J Clin Oncol. 1997;15:76-84.
11. Rosen G, Caparros B, Huvos AG, et al. Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on response of the primary tumor to preoperative chemotherapy. Cancer. 1982;49:1221-1230.
12. Bacci G, Ferrari S, Longhi A, et al. Delayed methotrexate clearance in osteosarcoma patients treated with multiagent regimens of neoadjuvant chemotherapy. Oncol Rep. 2003;10:851-857.
13. Kalifa C, Razafindrakoto H, Vassal G, et al. Chemotherapy in osteogenic sarcoma: the experience of the pediatric department of the Goustave Roussy Institute. Cancer Treat Res. 1993;62:347-349.
14. Herson J, Sutow W, Elder K, et al. Adjuvant chemotherapy in nonmetastatic osteosarcoma: a Southwest Oncology Group study. Med Pediatr Oncol. 1980;8:343-352.
15. Rytting M, Pearson P, Raymond AK, et al. Osteosarcoma in preadolescent patients. Clin Orthop. 2000;373:39-50.
16. Brostrom LA, Strander H, Nilsonne U. Survival in osteosarcoma in relation to tumor size and location. Clin Orthop. 1982;167:250-254.
17. McKenna RJ, Schwinn CP, Soong KY, et al. Osteosarcomata of the osteogenic series (osteosarcoma, fibrosarcoma, chondrosarcoma, parosteal osteogenic sarcoma and sarcomata arising in the normal bone). J Bone Joint Surg [Am]. 1966;48:1-26.
18. Bacci G, Picci P, Ruggieri P, et al. Primary chemotherapy and delayed surgery (neoadjuvant chemotherapy) for osteosarcoma of the extremities. The Istituto Ortopedico Rizzoli experience in 127 patients treated preoperatively with intravenous methotrexate (high versus moderate doses) and intraarterial cisplatin. Cancer. 1990;65:2539-2553.
19. Bacci G, Briccoli A, Ferrari S, et al. Neoadjuvant chemotherapy for osteosarcoma of the extremity: long-term results of the Rizzoli's 4th protocol. Eur J Cancer. 2001;37:2030-2039.
20. Ferrari S, Mercuri M, Picci P, et al. Nonmetastatic osteosarcoma of the extremity: results of a neoadjuvant chemotherapy protocol (IOR/OS-3) with high-dose methotrexate, intraarterial or intravenous cisplatin, doxorubicin, and salvage chemotherapy based on histologic tumor response. Tumori. 1999;85:458-464.
21. Smeland S, Bacci G, Ferrari S, et al. Neoadjuvant chemotherapy with high-dose ifosfamide added to methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity. A joint study by the Italian (ISG) and Scandinavian sarcoma groups [abstract]. Proceedings ASCO. 2003:817.
22. Enneking WF. Modification of the System for Functional Evaluation of Surgical Management of Musculoskeletal Oncology. New York: Churchill Livingstone, 1987.
23. Picci P, Bacci G, Campanacci M, et al. Histologic evaluation of necrosis in osteosarcoma induced by chemotherapy. Cancer. 1985;56:1515-1521.
24. Hryniuk W, Bush H. The importance of dose-intensity in chemotherapy of metastatic breast cancer. J Clin Oncol. 1984;2:1281-1288.
25. Bieling P, Bielack S, Delling G, et al. Neoadjuvant chemotherapy of osteosarcoma. Preliminary results of the cooperative COSS-86 osteosarcoma study. Clin Orthop. 1991;270:79-86.
26. Taylor WF, Ivins JC, Pritchard DJ, et al. Trends and variability in survival among patients with osteosarcoma. A 7-year update. Mayo Clin Proc. 1985;60:91-104.